View Future GrowthAccrelist 과거 순이익 실적과거 기준 점검 0/6Accrelist은 연평균 4.5%의 비율로 수입이 증가해 온 반면, Electronic 산업은 연평균 2.8%의 비율로 감소했습니다. 매출은 연평균 51.7%의 비율로 감소했습니다.핵심 정보4.47%순이익 성장률7.28%주당순이익(EPS) 성장률Electronic 산업 성장률5.20%매출 성장률-51.74%자기자본이익률-58.57%순이익률-33.93%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트Reported Earnings • Sep 13Full year 2025 earnings released: S$0.01 loss per share (vs S$0.021 loss in FY 2024)Full year 2025 results: S$0.01 loss per share (improved from S$0.021 loss in FY 2024). Revenue: S$15.7m (down 6.0% from FY 2024). Net loss: S$3.14m (loss narrowed 53% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 16First half 2024 earnings releasedFirst half 2024 results: Revenue: S$8.30m (down 84% from 1H 2023). Net income: S$5.36m (up S$7.01m from 1H 2023). Profit margin: 65% (up from net loss in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 30Full year 2023 earnings releasedFull year 2023 results: Revenue: S$35.0m (down 86% from FY 2022). Net income: S$2.20m (up S$14.9m from FY 2022). Profit margin: 6.3% (up from net loss in FY 2022). The move to profitability was driven by lower expenses.Reported Earnings • Jun 02Full year 2022 earnings released: S$0.007 loss per share (vs S$0.002 loss in FY 2021)Full year 2022 results: S$0.007 loss per share (down from S$0.002 loss in FY 2021). Revenue: S$242.0m (up 60% from FY 2021). Net loss: S$1.92m (loss widened 232% from FY 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 18Full year 2021 earnings released: S$0.002 loss per share (vs S$0.043 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.3m (up 8.9% from FY 2020). Net loss: S$579.0k (loss narrowed 95% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Jun 05Full year 2021 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.7m (up 9.3% from FY 2020). Net loss: S$127.0k (loss narrowed 99% from FY 2020).모든 업데이트 보기Recent updatesNew Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Singaporean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Significant insider selling over the past 3 months (S$1.3m sold). Market cap is less than US$100m (S$16.1m market cap, or US$12.5m).New Risk • Dec 10New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: S$500k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (S$500k sold). Market cap is less than US$100m (S$16.1m market cap, or US$12.4m).New Risk • Nov 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (S$13.5m market cap, or US$10.4m).Reported Earnings • Sep 13Full year 2025 earnings released: S$0.01 loss per share (vs S$0.021 loss in FY 2024)Full year 2025 results: S$0.01 loss per share (improved from S$0.021 loss in FY 2024). Revenue: S$15.7m (down 6.0% from FY 2024). Net loss: S$3.14m (loss narrowed 53% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Sep 13Accrelist Ltd., Annual General Meeting, Sep 29, 2025Accrelist Ltd., Annual General Meeting, Sep 29, 2025, at 13:00 Singapore Standard Time. Location: 10 ubi crescent, 02-07, ubi techpark lobby a, singapore 408564, SingaporeNew Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$11.2m market cap, or US$8.67m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Singaporean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$11.8m market cap, or US$8.85m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).New Risk • Nov 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Market cap is less than US$10m (S$12.5m market cap, or US$9.30m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).New Risk • Oct 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: S$12.8m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$9.7m free cash flow). Market cap is less than US$10m (S$12.8m market cap, or US$9.78m). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).New Risk • Sep 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$9.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (S$14.4m market cap, or US$11.0m).공시 • Jul 17Accrelist Ltd., Annual General Meeting, Jul 31, 2024Accrelist Ltd., Annual General Meeting, Jul 31, 2024, at 13:00 Singapore Standard Time. Location: 10 ubi crescent, 02-07, ubi techpark lobby a, singapore 408564, Singapore공시 • Jul 10Accrelist Ltd. Announces Retirement of Ng Li Yong as Lead Independent DirectorAccrelist Ltd. announced that Ng Li Yong not be seeking re-election and will retire as the Lead Independent Director of the Company at the close of forthcoming annual general meeting of the Company after having served on the Board for an aggregate period of more than 9 years. Upon his retirement, Mr. Ng will step down from his position as the Lead Independent Director, Chairman of the Nominating Committee and Remuneration Committee, and a member of the Audit Committee of the Company. In view of Mr. Ng's retirement, the positions of Chairman of the Nominating Committee and Remuneration Committee will become vacant until the appointment of a new Chairman of the Nominating Committee and Remuneration Committee by the Board as soon as practicable. Based on its enquiries and to the best of its knowledge, the Sponsor is satisfied that, save as disclosed in this announcement, there are no other material reasons for the retirement of Mr. Ng. The Company will be assessing suitable candidates to fill the vacancy to meet the minimum number of members within the Audit Committee of the Company pursuant to the Catalist Rules. Other DirectorShips Past C&G Environmental Protection Holdings Limited.공시 • Jul 04Accrelist to Acquire 60% Stake in Nanjing Yi Chuangyuan Health ManagementCatalist-listed Accrelist Ltd. (Catalist:QZG) intends to acquire a 60% equity stake in a health management company for CNY 1.5 million (SGD 280,000), the group said on July 3. Accrelist, which has business in skincare products, medical aesthetics and electronics solutions, will acquire 1.5 million newly issued and paid-up shares in Accrelist Nanjing, formerly known as Nanjing Yi Chuangyuan Health Management Co., Ltd. Information on Accrelist Nanjing's book value and net tangible asset value attributable to the sale shares as at March 31 is not available as the company "never prepared management accounts and/or financial statements", said Accrelist. It added: "There is no open market value of the shares of Accrelist Nanjing as the latter is not publicly traded and no valuation has been carried out in connection with the acquisition." The proposed acquisition will be funded entirely by Accrelist Medical Aesthetics (Hainan)'s internally available disposable resources, including loans it received from the group. Accrelist Medical Aesthetics (Hainan) is the group's 95% owned subsidiary. Following the acquisition, Accrelist's executive chairman and managing director Terence Tea will be appointed Accrelist Nanjing's legal representative and general manager for a term of two years. Mr. Tea said: "Accrelist Nanjing's foundation and comprehensive offerings provide a solid platform for growth. I am confident that our combined expertise and market knowledge will enable us to achieve significant milestones and create long-term value for our shareholders." The primary scope of business of Accrelist Nanjing ranges from remote health management services and traditional Chinese medicine to non-medical health services.New Risk • Jun 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$8.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$8.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$15.3m market cap, or US$11.4m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (97% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$15.0m market cap, or US$11.1m).New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: S$13.1m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (97% accrual ratio). Market cap is less than US$10m (S$13.1m market cap, or US$9.63m). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding).공시 • Mar 26Accrelist Ltd. Announces Board and Committee ChangesThe Board of Directors of Accrelist Ltd. announced that Mr. Chin Sek Peng ("Mr. Chin") has been appointed as an Independent and Non-Executive Director of the Company with effect from 26 March 2024. Following his appointment to the Board, Mr. Chin shall also be appointed as the Chairman of the Audit Committee and member of the Remuneration and Nomination Committee of the Company. Mr. Yeo Hwee Tiong ("Mr. Yeo") has resigned as the Independent and Non-Executive Director of the Company with his effective cessation date being 5 April 2024 ("Cessation"). Following his resignation, Mr. Yeo will relinquish his position as a member of the Audit Committee and member of the Remuneration Committee of the Company. Following the appointment of Mr. Chin and the Cessation, the composition of the Board and Board Committees of the Company, will be as follows: Board of Directors:- Dr. Terence Tea Yeok Kian - Executive Chairman and Managing Director, Mr. Ng Li Yong - Lead Independent Director,Mr. Chin Sek Peng - Independent and Non-Executive Director. Audit Committee:- Mr. Chin Sek Peng (Chairman), Mr. Ng Li Yong (Member). Remuneration Committee:- Mr. Ng Li Yong (Chairman), Mr. Chin Sek Peng (Member). Nominating Committee:- Mr. Ng Li Yong (Chairman), Mr. Chin Sek Peng (Member).Recent Insider Transactions • Jan 05Executive Chairman recently bought S$76k worth of stockOn the 3rd of January, Yeok Kian Tea bought around 2m shares on-market at roughly S$0.037 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yeok Kian has been a buyer over the last 12 months, purchasing a net total of S$218k worth in shares.Reported Earnings • Nov 16First half 2024 earnings releasedFirst half 2024 results: Revenue: S$8.30m (down 84% from 1H 2023). Net income: S$5.36m (up S$7.01m from 1H 2023). Profit margin: 65% (up from net loss in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.공시 • Nov 10Accrelist Ltd., Annual General Meeting, Nov 28, 2023Accrelist Ltd., Annual General Meeting, Nov 28, 2023, at 10:00 Singapore Standard Time. Location: 10 Ubi Crescent, #02-07 Ubi Techpark Lobby A Singapore Singapore Agenda: To receive and adopt the Directors' Statement and the Audited Financial Statements for the financial year ended 31 March 2023 together with the Auditors' Report thereon; to approve the payment of Directors' fees of SGD 180,000 for the financial year ending 31 March 2024, to be paid semi-annually in arrears (FY2023: SGD 180,000); to re-elect the executives; to re-appoint Moore Stephens LLP as Auditors of the Company and to authorize the Directors of the Company to fix their remuneration; and to consider the other resolutions.Buying Opportunity • Nov 09Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 39%. The fair value is estimated to be S$0.045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Meanwhile, the company has become profitable.New Risk • Oct 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: S$12.8m (US$9.37m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$12.8m market cap, or US$9.37m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.8% increase in shares outstanding).New Risk • Sep 06New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 111% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$17.2m market cap, or US$12.6m).Reported Earnings • Aug 30Full year 2023 earnings releasedFull year 2023 results: Revenue: S$35.0m (down 86% from FY 2022). Net income: S$2.20m (up S$14.9m from FY 2022). Profit margin: 6.3% (up from net loss in FY 2022). The move to profitability was driven by lower expenses.New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$16.5m market cap, or US$12.5m).New Risk • Jul 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (S$15.5m market cap, or US$11.7m).New Risk • Jul 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (S$17.0m market cap, or US$12.9m).공시 • Jun 07Accrelist Ltd. Appoints Yeo Hwee Tiong as Independent and Non-Executive Director, Member of the Audit Committee and the Remuneration Committee, Effective 1 July 2023The Board of Directors of Accrelist Ltd. approved the appointment of Mr. Yeo Hwee Tiong as an Independent and Non-Executive Director of the Company with effect from 1 July 2023. Mr. Yeo shall also be appointed as a member of the Audit Committee and the Remuneration Committee of the Company. The Board of Directors considers Mr. Yeo to be independent for the purpose of Rule 704(7) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited. Working Experience; 1. January 2021 - Present (Clermont Holdings Healthcare Group) - Senior Advisor 2. August 2021 - 31 March 2023 (Hoan My Group) - Executive Chairman 3. 2018 - 2020 (Singapore Women's & Children's Medical Group Pte. Ltd.) - Executive Chairman and Group Chief Executive Officer 4. 2014 - 2018 (KPMG Singapore LLP) - Principal, Healthcare Lead, Singapore & Asia Pacific 5. 2012 - 2014 (Econ Healthcare Group) - Managing Director. Other DirectorShips Past; Singapore Women's & Children s Medical Group Pte. Ltd. - Hoan My Medical Corporation - Hoan My Saigon Hospital - Hanh Phuc Hospital - Hoan My Dong Nai-ITO Hospital - Hoan My Health Services Company - Hoan My Health Services Consultancy - Huu Nghi Health Consultancy - The Medical City - Tan Wee Khin Pte. Ltd. - Dr. Madeleine Tan Pte. Ltd. - Singapore Women's Clinic (Tampines) Pte. Ltd. - Surgery & Gynaecology Pte. Ltd. - Dr Paul Tseng Pte. Ltd. - ABCC Pte. Ltd. - J and T Consultants Pte. Ltd. - Anson International Paediatric & Child Development Clinic Pte. Ltd. - BT Medical Pte. Ltd. - Jasmine Mohd Pte. Ltd. - Mark Loh Paediatrics Pte. Ltd. - Singapore Healthbridge Pte. Ltd. - Singapore Women's Medical Group Pte. Ltd. - Singapore Children's Medical Group Pte. Ltd. - Dr Janice Paediatric Centre Pte. Ltd. - Ong XH Clinic for Women Pte. Ltd. - C.H.Koh Clinic For Women Pte. Ltd. - Paediatric Allergy Immunology Rheumatology Centre Pte. Ltd. - Shilla Mariah Clinic For Women Pte. Ltd. - Singapore Red Cross (Council Member) - The Management Development Institute of Singapore o School of Life Sciences Industrial Advisory Board (Member) o Academic Advisory Board (Member) o MDIS Senate (Member). Other DirectorShips Present; Senior Advisor, Clermont Holdings Pte. Ltd. - Member, Singapore Institute of Directors - Independent Director of Cordlife Group Limited. Director Experience Details; Mr. Yeo is an Independent Director of Cordlife Group Limited and has attended the mandatory director training. Professional Qualifications; Mr. Yeo obtained his Bachelor of Science (Building) from Heriot-Watt University, Edinburgh, United Kingdom. He also holds a Master of Science (Project Management) from National University of Singapore. Following the appointment of Mr. Yeo, the composition of the Board and Board Committees of the Company with effect from 1 July 2023, will be as follows: Board of Directors;Dr. Terence Tea Yeok Kian as Executive Chairman and Managing Director, Mr. Ng Li Yong as Lead Independent Director, Mr. Lim Yeow Hua @ Lim You Qin as Independent and Non-Executive Director and Mr. Yeo Hwee Tiong as Independent and Non-Executive Director. Audit Committee; Mr. Lim Yeow Hua @ Lim You Qin (Chairman), Mr. Ng Li Yong (Member), Mr. Yeo Hwee Tiong (Member). Remuneration Committee; Mr. Ng Li Yong (Chairman), Mr. Lim Yeow Hua @ Lim You Qin (Member)Mr Yeo Hwee Tiong (Member). Nominating Committee; Mr. Ng Li Yong (Chairman), Mr. Lim Yeow Hua @ Lim You Qin (Member)Dr. Terence Tea Yeok Kian (Member).Recent Insider Transactions • Jan 20Executive Chairman recently bought S$53k worth of stockOn the 17th of January, Yeok Kian Tea bought around 1m shares on-market at roughly S$0.049 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yeok Kian has been a buyer over the last 12 months, purchasing a net total of S$100k worth in shares.Board Change • Jan 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Non-Executive Director Kenny Lim was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Non-Executive Director Kenny Lim was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 12+ 2 more updatesAccrelist Ltd. Announces Retirement of Kang Pang Kiang as Non-Independent and Non-Executive Director and Member of Audit Committee and Remuneration CommitteeAccrelist Ltd. announced retirement of Kang Pang Kiang as Non-Independent and Non-Executive Director. Mr. Kang Pang Kiang will be retiring as a Non-Independent and Non-Executive Director of the Company pursuant to Regulation 91 of the Company's Constitution. Accordingly, he shall retire at the conclusion of the Company's upcoming Annual General Meeting to be held on 28 November 2022 and relinquish his position as member of Audit Committee and Remuneration Committee.공시 • Jul 23Accrelist Ltd., Annual General Meeting, Sep 29, 2022Accrelist Ltd., Annual General Meeting, Sep 29, 2022.Reported Earnings • Jun 02Full year 2022 earnings released: S$0.007 loss per share (vs S$0.002 loss in FY 2021)Full year 2022 results: S$0.007 loss per share (down from S$0.002 loss in FY 2021). Revenue: S$242.0m (up 60% from FY 2021). Net loss: S$1.92m (loss widened 232% from FY 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Executive Departure • Oct 11Company Secretary Wei Hsiung Lee has left the companyOn the 1st of October, Wei Hsiung Lee's tenure as Company Secretary ended after 9.6 years in the role. We don't have any record of a personal shareholding under Wei Hsiung's name. Wei Hsiung is the only executive to leave the company over the last 12 months.공시 • Sep 11Dame Dato Sri Marilyn Tay Bee Choo entered into a shareholders’ agreement to acquire 30% stake in Accrelist Medical Aesthetics (SPC) Pte. Ltd. from Accrelist Ltd. (Catalist:QZG) for SGD 1 million.Dame Dato Sri Marilyn Tay Bee Choo entered into a shareholders’ agreement to acquire 30% stake in Accrelist Medical Aesthetics (SPC) Pte. Ltd. from Accrelist Ltd. (Catalist:QZG) for SGD 1 million on September 10, 2021. The Consideration will be settled by cash and the transaction involves acquisition of 30,000 shares. The Company intends to utilise the entirety of the proceeds of the transaction for general working capital purposes.공시 • Aug 31Accrelist Ltd. has completed a Follow-on Equity Offering in the amount of SGD 1.62162 million.Accrelist Ltd. has completed a Follow-on Equity Offering in the amount of SGD 1.62162 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,000,000 Price\Range: SGD 0.07371 Transaction Features: Subsequent Direct ListingReported Earnings • Jul 18Full year 2021 earnings released: S$0.002 loss per share (vs S$0.043 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.3m (up 8.9% from FY 2020). Net loss: S$579.0k (loss narrowed 95% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Jun 12Insider recently bought S$62k worth of stockOn the 9th of June, Soon Huat Toh bought around 1m shares on-market at roughly S$0.046 per share. In the last 3 months, they made an even bigger purchase worth S$176k. Insiders have collectively bought S$257k more in shares than they have sold in the last 12 months.Reported Earnings • Jun 05Full year 2021 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.7m (up 9.3% from FY 2020). Net loss: S$127.0k (loss narrowed 99% from FY 2020).Recent Insider Transactions • May 27Insider recently bought S$176k worth of stockOn the 24th of May, Soon Huat Toh bought around 4m shares on-market at roughly S$0.045 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought S$195k more in shares than they have sold in the last 12 months.공시 • Nov 11Accrelist Ltd., Annual General Meeting, Nov 26, 2020Accrelist Ltd., Annual General Meeting, Nov 26, 2020, at 14:00 Singapore Standard Time. Agenda: To adopt directors statement and audited financial statements for the year ended March 31, 2020; to approve director fee; to re-elect directors; to reappoint auditors and to fix their remuneration; to allot and issue new shares; to approve share buyback mandate; and to approve other matters.Reported Earnings • Sep 30Full year earnings releasedOver the last 12 months the company has reported total losses of S$10.2m, with earnings decreasing by S$10.4m from the prior year. Total revenue was S$138.9m over the last 12 months, down 17% from the prior year.공시 • Sep 19Accrelist Ltd. (Catalist:QZG) entered into a term sheet agreement to acquire The Wellness Clinic Pte. Ltd from Verita Healthcare Group Limited for SGD 16.9 million.Accrelist Ltd. (Catalist:QZG) entered into a term sheet agreement to acquire The Wellness Clinic Pte. Ltd from Verita Healthcare Group Limited for SGD 16.9 million on September 17, 2019. The consideration will be paid in cash and issue of ordinary shares of Accrelist Ltd. (Catalist:QZG) to Verita Healthcare Group Limited. The transaction will be funded through the combination of internal resources and/or the fund raising exercise. In connection with the transaction, Verita Healthcare Group Limited has also granted an exclusivity period of 12 weeks to the Accrelist Ltd to conduct due diligence. The term sheet agreement will expire on the execution of the definitive agreement or the expiry of the exclusivity period. The transaction is subject to the execution of definitive agreement, due diligence, regulatory approval, Accrelist Ltd shareholders approval and completion of fund raising exercise by the Accrelist Ltd for the acquisition. The transaction is approved by Verita Healthcare Group Limited shareholders. W Capital Markets Pte Ltd acted as financial advisor to Accrelist Ltd.매출 및 비용 세부 내역Accrelist가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이Catalist:QZG 매출, 비용 및 순이익 (SGD Millions)날짜매출순이익일반관리비연구개발비30 Sep 2512-413030 Jun 2513-413031 Mar 2514-514031 Dec 2415-411030 Sep 2414-412030 Jun 2414-611031 Mar 2413-710031 Dec 2315-39030 Sep 231809030 Jun 231819031 Mar 2319310030 Sep 22-70-1010030 Jun 22-15-911031 Mar 2241-912031 Dec 21226-616030 Sep 21211016030 Jun 21181014031 Mar 21151-113031 Dec 20135-513030 Sep 20118-1014030 Jun 20128-1115031 Mar 20139-1217031 Dec 19150-717030 Sep 19160-118030 Jun 19164-117031 Mar 19167016031 Dec 18164115030 Sep 18161214030 Jun 18137112031 Mar 18112010031 Dec 1776-57030 Sep 1740-104030 Jun 1720-93031 Mar 171-83031 Dec 162-93030 Sep 162-83030 Jun 163-93031 Mar 164-93031 Dec 15-48-73030 Sep 15-37-43030 Jun 15-14-250양질의 수익: QZG 은(는) 현재 수익성이 없습니다.이익 마진 증가: QZG는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: QZG는 수익성이 없지만 지난 5년 동안 연평균 4.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 QZG의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: QZG은 수익성이 없어 지난 해 수익 성장률을 Electronic 업계(-2.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: QZG는 현재 수익성이 없으므로 자본 수익률이 음수(-58.57%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YTech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 20:21종가2026/05/25 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Accrelist Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Sep 13Full year 2025 earnings released: S$0.01 loss per share (vs S$0.021 loss in FY 2024)Full year 2025 results: S$0.01 loss per share (improved from S$0.021 loss in FY 2024). Revenue: S$15.7m (down 6.0% from FY 2024). Net loss: S$3.14m (loss narrowed 53% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 16First half 2024 earnings releasedFirst half 2024 results: Revenue: S$8.30m (down 84% from 1H 2023). Net income: S$5.36m (up S$7.01m from 1H 2023). Profit margin: 65% (up from net loss in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 30Full year 2023 earnings releasedFull year 2023 results: Revenue: S$35.0m (down 86% from FY 2022). Net income: S$2.20m (up S$14.9m from FY 2022). Profit margin: 6.3% (up from net loss in FY 2022). The move to profitability was driven by lower expenses.
Reported Earnings • Jun 02Full year 2022 earnings released: S$0.007 loss per share (vs S$0.002 loss in FY 2021)Full year 2022 results: S$0.007 loss per share (down from S$0.002 loss in FY 2021). Revenue: S$242.0m (up 60% from FY 2021). Net loss: S$1.92m (loss widened 232% from FY 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 18Full year 2021 earnings released: S$0.002 loss per share (vs S$0.043 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.3m (up 8.9% from FY 2020). Net loss: S$579.0k (loss narrowed 95% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jun 05Full year 2021 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.7m (up 9.3% from FY 2020). Net loss: S$127.0k (loss narrowed 99% from FY 2020).
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Singaporean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Significant insider selling over the past 3 months (S$1.3m sold). Market cap is less than US$100m (S$16.1m market cap, or US$12.5m).
New Risk • Dec 10New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: S$500k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (S$500k sold). Market cap is less than US$100m (S$16.1m market cap, or US$12.4m).
New Risk • Nov 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$3.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (S$13.5m market cap, or US$10.4m).
Reported Earnings • Sep 13Full year 2025 earnings released: S$0.01 loss per share (vs S$0.021 loss in FY 2024)Full year 2025 results: S$0.01 loss per share (improved from S$0.021 loss in FY 2024). Revenue: S$15.7m (down 6.0% from FY 2024). Net loss: S$3.14m (loss narrowed 53% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Sep 13Accrelist Ltd., Annual General Meeting, Sep 29, 2025Accrelist Ltd., Annual General Meeting, Sep 29, 2025, at 13:00 Singapore Standard Time. Location: 10 ubi crescent, 02-07, ubi techpark lobby a, singapore 408564, Singapore
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$11.2m market cap, or US$8.67m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Singaporean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$11.8m market cap, or US$8.85m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
New Risk • Nov 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Market cap is less than US$10m (S$12.5m market cap, or US$9.30m). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
New Risk • Oct 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: S$12.8m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$9.7m free cash flow). Market cap is less than US$10m (S$12.8m market cap, or US$9.78m). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
New Risk • Sep 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$9.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (S$14.4m market cap, or US$11.0m).
공시 • Jul 17Accrelist Ltd., Annual General Meeting, Jul 31, 2024Accrelist Ltd., Annual General Meeting, Jul 31, 2024, at 13:00 Singapore Standard Time. Location: 10 ubi crescent, 02-07, ubi techpark lobby a, singapore 408564, Singapore
공시 • Jul 10Accrelist Ltd. Announces Retirement of Ng Li Yong as Lead Independent DirectorAccrelist Ltd. announced that Ng Li Yong not be seeking re-election and will retire as the Lead Independent Director of the Company at the close of forthcoming annual general meeting of the Company after having served on the Board for an aggregate period of more than 9 years. Upon his retirement, Mr. Ng will step down from his position as the Lead Independent Director, Chairman of the Nominating Committee and Remuneration Committee, and a member of the Audit Committee of the Company. In view of Mr. Ng's retirement, the positions of Chairman of the Nominating Committee and Remuneration Committee will become vacant until the appointment of a new Chairman of the Nominating Committee and Remuneration Committee by the Board as soon as practicable. Based on its enquiries and to the best of its knowledge, the Sponsor is satisfied that, save as disclosed in this announcement, there are no other material reasons for the retirement of Mr. Ng. The Company will be assessing suitable candidates to fill the vacancy to meet the minimum number of members within the Audit Committee of the Company pursuant to the Catalist Rules. Other DirectorShips Past C&G Environmental Protection Holdings Limited.
공시 • Jul 04Accrelist to Acquire 60% Stake in Nanjing Yi Chuangyuan Health ManagementCatalist-listed Accrelist Ltd. (Catalist:QZG) intends to acquire a 60% equity stake in a health management company for CNY 1.5 million (SGD 280,000), the group said on July 3. Accrelist, which has business in skincare products, medical aesthetics and electronics solutions, will acquire 1.5 million newly issued and paid-up shares in Accrelist Nanjing, formerly known as Nanjing Yi Chuangyuan Health Management Co., Ltd. Information on Accrelist Nanjing's book value and net tangible asset value attributable to the sale shares as at March 31 is not available as the company "never prepared management accounts and/or financial statements", said Accrelist. It added: "There is no open market value of the shares of Accrelist Nanjing as the latter is not publicly traded and no valuation has been carried out in connection with the acquisition." The proposed acquisition will be funded entirely by Accrelist Medical Aesthetics (Hainan)'s internally available disposable resources, including loans it received from the group. Accrelist Medical Aesthetics (Hainan) is the group's 95% owned subsidiary. Following the acquisition, Accrelist's executive chairman and managing director Terence Tea will be appointed Accrelist Nanjing's legal representative and general manager for a term of two years. Mr. Tea said: "Accrelist Nanjing's foundation and comprehensive offerings provide a solid platform for growth. I am confident that our combined expertise and market knowledge will enable us to achieve significant milestones and create long-term value for our shareholders." The primary scope of business of Accrelist Nanjing ranges from remote health management services and traditional Chinese medicine to non-medical health services.
New Risk • Jun 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$8.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$8.7m free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$15.3m market cap, or US$11.4m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (97% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$15.0m market cap, or US$11.1m).
New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: S$13.1m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (97% accrual ratio). Market cap is less than US$10m (S$13.1m market cap, or US$9.63m). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding).
공시 • Mar 26Accrelist Ltd. Announces Board and Committee ChangesThe Board of Directors of Accrelist Ltd. announced that Mr. Chin Sek Peng ("Mr. Chin") has been appointed as an Independent and Non-Executive Director of the Company with effect from 26 March 2024. Following his appointment to the Board, Mr. Chin shall also be appointed as the Chairman of the Audit Committee and member of the Remuneration and Nomination Committee of the Company. Mr. Yeo Hwee Tiong ("Mr. Yeo") has resigned as the Independent and Non-Executive Director of the Company with his effective cessation date being 5 April 2024 ("Cessation"). Following his resignation, Mr. Yeo will relinquish his position as a member of the Audit Committee and member of the Remuneration Committee of the Company. Following the appointment of Mr. Chin and the Cessation, the composition of the Board and Board Committees of the Company, will be as follows: Board of Directors:- Dr. Terence Tea Yeok Kian - Executive Chairman and Managing Director, Mr. Ng Li Yong - Lead Independent Director,Mr. Chin Sek Peng - Independent and Non-Executive Director. Audit Committee:- Mr. Chin Sek Peng (Chairman), Mr. Ng Li Yong (Member). Remuneration Committee:- Mr. Ng Li Yong (Chairman), Mr. Chin Sek Peng (Member). Nominating Committee:- Mr. Ng Li Yong (Chairman), Mr. Chin Sek Peng (Member).
Recent Insider Transactions • Jan 05Executive Chairman recently bought S$76k worth of stockOn the 3rd of January, Yeok Kian Tea bought around 2m shares on-market at roughly S$0.037 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yeok Kian has been a buyer over the last 12 months, purchasing a net total of S$218k worth in shares.
Reported Earnings • Nov 16First half 2024 earnings releasedFirst half 2024 results: Revenue: S$8.30m (down 84% from 1H 2023). Net income: S$5.36m (up S$7.01m from 1H 2023). Profit margin: 65% (up from net loss in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
공시 • Nov 10Accrelist Ltd., Annual General Meeting, Nov 28, 2023Accrelist Ltd., Annual General Meeting, Nov 28, 2023, at 10:00 Singapore Standard Time. Location: 10 Ubi Crescent, #02-07 Ubi Techpark Lobby A Singapore Singapore Agenda: To receive and adopt the Directors' Statement and the Audited Financial Statements for the financial year ended 31 March 2023 together with the Auditors' Report thereon; to approve the payment of Directors' fees of SGD 180,000 for the financial year ending 31 March 2024, to be paid semi-annually in arrears (FY2023: SGD 180,000); to re-elect the executives; to re-appoint Moore Stephens LLP as Auditors of the Company and to authorize the Directors of the Company to fix their remuneration; and to consider the other resolutions.
Buying Opportunity • Nov 09Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 39%. The fair value is estimated to be S$0.045, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Meanwhile, the company has become profitable.
New Risk • Oct 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: S$12.8m (US$9.37m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (S$12.8m market cap, or US$9.37m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.8% increase in shares outstanding).
New Risk • Sep 06New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 111% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$17.2m market cap, or US$12.6m).
Reported Earnings • Aug 30Full year 2023 earnings releasedFull year 2023 results: Revenue: S$35.0m (down 86% from FY 2022). Net income: S$2.20m (up S$14.9m from FY 2022). Profit margin: 6.3% (up from net loss in FY 2022). The move to profitability was driven by lower expenses.
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (S$16.5m market cap, or US$12.5m).
New Risk • Jul 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (S$15.5m market cap, or US$11.7m).
New Risk • Jul 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 33% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (S$17.0m market cap, or US$12.9m).
공시 • Jun 07Accrelist Ltd. Appoints Yeo Hwee Tiong as Independent and Non-Executive Director, Member of the Audit Committee and the Remuneration Committee, Effective 1 July 2023The Board of Directors of Accrelist Ltd. approved the appointment of Mr. Yeo Hwee Tiong as an Independent and Non-Executive Director of the Company with effect from 1 July 2023. Mr. Yeo shall also be appointed as a member of the Audit Committee and the Remuneration Committee of the Company. The Board of Directors considers Mr. Yeo to be independent for the purpose of Rule 704(7) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited. Working Experience; 1. January 2021 - Present (Clermont Holdings Healthcare Group) - Senior Advisor 2. August 2021 - 31 March 2023 (Hoan My Group) - Executive Chairman 3. 2018 - 2020 (Singapore Women's & Children's Medical Group Pte. Ltd.) - Executive Chairman and Group Chief Executive Officer 4. 2014 - 2018 (KPMG Singapore LLP) - Principal, Healthcare Lead, Singapore & Asia Pacific 5. 2012 - 2014 (Econ Healthcare Group) - Managing Director. Other DirectorShips Past; Singapore Women's & Children s Medical Group Pte. Ltd. - Hoan My Medical Corporation - Hoan My Saigon Hospital - Hanh Phuc Hospital - Hoan My Dong Nai-ITO Hospital - Hoan My Health Services Company - Hoan My Health Services Consultancy - Huu Nghi Health Consultancy - The Medical City - Tan Wee Khin Pte. Ltd. - Dr. Madeleine Tan Pte. Ltd. - Singapore Women's Clinic (Tampines) Pte. Ltd. - Surgery & Gynaecology Pte. Ltd. - Dr Paul Tseng Pte. Ltd. - ABCC Pte. Ltd. - J and T Consultants Pte. Ltd. - Anson International Paediatric & Child Development Clinic Pte. Ltd. - BT Medical Pte. Ltd. - Jasmine Mohd Pte. Ltd. - Mark Loh Paediatrics Pte. Ltd. - Singapore Healthbridge Pte. Ltd. - Singapore Women's Medical Group Pte. Ltd. - Singapore Children's Medical Group Pte. Ltd. - Dr Janice Paediatric Centre Pte. Ltd. - Ong XH Clinic for Women Pte. Ltd. - C.H.Koh Clinic For Women Pte. Ltd. - Paediatric Allergy Immunology Rheumatology Centre Pte. Ltd. - Shilla Mariah Clinic For Women Pte. Ltd. - Singapore Red Cross (Council Member) - The Management Development Institute of Singapore o School of Life Sciences Industrial Advisory Board (Member) o Academic Advisory Board (Member) o MDIS Senate (Member). Other DirectorShips Present; Senior Advisor, Clermont Holdings Pte. Ltd. - Member, Singapore Institute of Directors - Independent Director of Cordlife Group Limited. Director Experience Details; Mr. Yeo is an Independent Director of Cordlife Group Limited and has attended the mandatory director training. Professional Qualifications; Mr. Yeo obtained his Bachelor of Science (Building) from Heriot-Watt University, Edinburgh, United Kingdom. He also holds a Master of Science (Project Management) from National University of Singapore. Following the appointment of Mr. Yeo, the composition of the Board and Board Committees of the Company with effect from 1 July 2023, will be as follows: Board of Directors;Dr. Terence Tea Yeok Kian as Executive Chairman and Managing Director, Mr. Ng Li Yong as Lead Independent Director, Mr. Lim Yeow Hua @ Lim You Qin as Independent and Non-Executive Director and Mr. Yeo Hwee Tiong as Independent and Non-Executive Director. Audit Committee; Mr. Lim Yeow Hua @ Lim You Qin (Chairman), Mr. Ng Li Yong (Member), Mr. Yeo Hwee Tiong (Member). Remuneration Committee; Mr. Ng Li Yong (Chairman), Mr. Lim Yeow Hua @ Lim You Qin (Member)Mr Yeo Hwee Tiong (Member). Nominating Committee; Mr. Ng Li Yong (Chairman), Mr. Lim Yeow Hua @ Lim You Qin (Member)Dr. Terence Tea Yeok Kian (Member).
Recent Insider Transactions • Jan 20Executive Chairman recently bought S$53k worth of stockOn the 17th of January, Yeok Kian Tea bought around 1m shares on-market at roughly S$0.049 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Yeok Kian has been a buyer over the last 12 months, purchasing a net total of S$100k worth in shares.
Board Change • Jan 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Non-Executive Director Kenny Lim was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. Independent Non-Executive Director Kenny Lim was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 12+ 2 more updatesAccrelist Ltd. Announces Retirement of Kang Pang Kiang as Non-Independent and Non-Executive Director and Member of Audit Committee and Remuneration CommitteeAccrelist Ltd. announced retirement of Kang Pang Kiang as Non-Independent and Non-Executive Director. Mr. Kang Pang Kiang will be retiring as a Non-Independent and Non-Executive Director of the Company pursuant to Regulation 91 of the Company's Constitution. Accordingly, he shall retire at the conclusion of the Company's upcoming Annual General Meeting to be held on 28 November 2022 and relinquish his position as member of Audit Committee and Remuneration Committee.
공시 • Jul 23Accrelist Ltd., Annual General Meeting, Sep 29, 2022Accrelist Ltd., Annual General Meeting, Sep 29, 2022.
Reported Earnings • Jun 02Full year 2022 earnings released: S$0.007 loss per share (vs S$0.002 loss in FY 2021)Full year 2022 results: S$0.007 loss per share (down from S$0.002 loss in FY 2021). Revenue: S$242.0m (up 60% from FY 2021). Net loss: S$1.92m (loss widened 232% from FY 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Executive Departure • Oct 11Company Secretary Wei Hsiung Lee has left the companyOn the 1st of October, Wei Hsiung Lee's tenure as Company Secretary ended after 9.6 years in the role. We don't have any record of a personal shareholding under Wei Hsiung's name. Wei Hsiung is the only executive to leave the company over the last 12 months.
공시 • Sep 11Dame Dato Sri Marilyn Tay Bee Choo entered into a shareholders’ agreement to acquire 30% stake in Accrelist Medical Aesthetics (SPC) Pte. Ltd. from Accrelist Ltd. (Catalist:QZG) for SGD 1 million.Dame Dato Sri Marilyn Tay Bee Choo entered into a shareholders’ agreement to acquire 30% stake in Accrelist Medical Aesthetics (SPC) Pte. Ltd. from Accrelist Ltd. (Catalist:QZG) for SGD 1 million on September 10, 2021. The Consideration will be settled by cash and the transaction involves acquisition of 30,000 shares. The Company intends to utilise the entirety of the proceeds of the transaction for general working capital purposes.
공시 • Aug 31Accrelist Ltd. has completed a Follow-on Equity Offering in the amount of SGD 1.62162 million.Accrelist Ltd. has completed a Follow-on Equity Offering in the amount of SGD 1.62162 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,000,000 Price\Range: SGD 0.07371 Transaction Features: Subsequent Direct Listing
Reported Earnings • Jul 18Full year 2021 earnings released: S$0.002 loss per share (vs S$0.043 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.3m (up 8.9% from FY 2020). Net loss: S$579.0k (loss narrowed 95% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Jun 12Insider recently bought S$62k worth of stockOn the 9th of June, Soon Huat Toh bought around 1m shares on-market at roughly S$0.046 per share. In the last 3 months, they made an even bigger purchase worth S$176k. Insiders have collectively bought S$257k more in shares than they have sold in the last 12 months.
Reported Earnings • Jun 05Full year 2021 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$151.7m (up 9.3% from FY 2020). Net loss: S$127.0k (loss narrowed 99% from FY 2020).
Recent Insider Transactions • May 27Insider recently bought S$176k worth of stockOn the 24th of May, Soon Huat Toh bought around 4m shares on-market at roughly S$0.045 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought S$195k more in shares than they have sold in the last 12 months.
공시 • Nov 11Accrelist Ltd., Annual General Meeting, Nov 26, 2020Accrelist Ltd., Annual General Meeting, Nov 26, 2020, at 14:00 Singapore Standard Time. Agenda: To adopt directors statement and audited financial statements for the year ended March 31, 2020; to approve director fee; to re-elect directors; to reappoint auditors and to fix their remuneration; to allot and issue new shares; to approve share buyback mandate; and to approve other matters.
Reported Earnings • Sep 30Full year earnings releasedOver the last 12 months the company has reported total losses of S$10.2m, with earnings decreasing by S$10.4m from the prior year. Total revenue was S$138.9m over the last 12 months, down 17% from the prior year.
공시 • Sep 19Accrelist Ltd. (Catalist:QZG) entered into a term sheet agreement to acquire The Wellness Clinic Pte. Ltd from Verita Healthcare Group Limited for SGD 16.9 million.Accrelist Ltd. (Catalist:QZG) entered into a term sheet agreement to acquire The Wellness Clinic Pte. Ltd from Verita Healthcare Group Limited for SGD 16.9 million on September 17, 2019. The consideration will be paid in cash and issue of ordinary shares of Accrelist Ltd. (Catalist:QZG) to Verita Healthcare Group Limited. The transaction will be funded through the combination of internal resources and/or the fund raising exercise. In connection with the transaction, Verita Healthcare Group Limited has also granted an exclusivity period of 12 weeks to the Accrelist Ltd to conduct due diligence. The term sheet agreement will expire on the execution of the definitive agreement or the expiry of the exclusivity period. The transaction is subject to the execution of definitive agreement, due diligence, regulatory approval, Accrelist Ltd shareholders approval and completion of fund raising exercise by the Accrelist Ltd for the acquisition. The transaction is approved by Verita Healthcare Group Limited shareholders. W Capital Markets Pte Ltd acted as financial advisor to Accrelist Ltd.